Inhibition of cyclinD1 and HDAC seems to affect two different deregulated targets in rhabdoid tumors, act synergistically and might be an attractive therapeutic approach for rhabdoid tumor treatment. The gene discussed is HDAC9; the disease is rhabdoid tumor.